BR0017063A - Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las - Google Patents

Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las

Info

Publication number
BR0017063A
BR0017063A BR0017063-1A BR0017063A BR0017063A BR 0017063 A BR0017063 A BR 0017063A BR 0017063 A BR0017063 A BR 0017063A BR 0017063 A BR0017063 A BR 0017063A
Authority
BR
Brazil
Prior art keywords
compounds
processes
pharmaceutical compositions
compositions containing
preparing
Prior art date
Application number
BR0017063-1A
Other languages
English (en)
Inventor
Klaus Rudolf
Wolfgang Eberlen
Alexander Dreyer
Stephan Georg Mueller
Henri Doods
Eckhart Bauer
Rudolf Hurnaus
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0017063A publication Critical patent/BR0017063A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"PIPERIDINAS SUBSTITUìDAS, COMPOSIçõES FARMACêUTICAS CONTENDO ESTES COMPOSTOS E PROCESSOS PARA PREPARá-LAS". A presente invenção refere-se à piperidinas substituídas de fórmula geral em que A^ 1^, A^ 2^, R, R^ 1^ e R^ 2^ são definidos como na reivindicação 1, os tautómeros, os diastereómeros, os enanciómeros, as misturas destes e os sais destes, particularmente os sais fisiologicamente aceitáveis destes com bases ou ácidos inorgânicos ou orgânicos, que têm propriedades farmacológicas valiosas, particularmente propriedades antagónicas de CGRP, composições farmacêuticas contendo estes compostos, seu uso e processos para prepará-los.
BR0017063-1A 1999-12-30 2000-12-22 Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las BR0017063A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19963868A DE19963868A1 (de) 1999-12-30 1999-12-30 Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
PCT/EP2000/013236 WO2001049676A1 (de) 1999-12-30 2000-12-22 Substituierte piperidine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
BR0017063A true BR0017063A (pt) 2002-10-22

Family

ID=7935059

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017063-1A BR0017063A (pt) 1999-12-30 2000-12-22 Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las

Country Status (28)

Country Link
US (1) US6949541B2 (pt)
EP (1) EP1252153A1 (pt)
JP (1) JP2003519222A (pt)
KR (1) KR100736063B1 (pt)
CN (1) CN1203069C (pt)
AR (1) AR027113A1 (pt)
AU (1) AU783275B2 (pt)
BG (1) BG106848A (pt)
BR (1) BR0017063A (pt)
CA (1) CA2395541C (pt)
CZ (1) CZ20022628A3 (pt)
DE (1) DE19963868A1 (pt)
EA (1) EA005600B1 (pt)
EE (1) EE200200369A (pt)
HR (1) HRP20020560A2 (pt)
HU (1) HUP0300002A3 (pt)
IL (2) IL150377A0 (pt)
MX (1) MXPA02006509A (pt)
NO (1) NO323700B1 (pt)
NZ (1) NZ519939A (pt)
PL (1) PL356400A1 (pt)
SK (1) SK9412002A3 (pt)
TW (1) TWI255267B (pt)
UA (1) UA75346C2 (pt)
UY (1) UY26513A1 (pt)
WO (1) WO2001049676A1 (pt)
YU (1) YU50002A (pt)
ZA (1) ZA200205181B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211770A1 (de) * 2002-03-14 2003-10-02 Boehringer Ingelheim Pharma Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK1539766T3 (en) * 2002-06-05 2017-04-03 Bristol Myers Squibb Co CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
WO2004091514A2 (en) * 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
WO2005013894A2 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
AU2004252150B2 (en) * 2003-06-26 2008-11-20 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7569578B2 (en) * 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
CA2549330A1 (en) 2003-12-05 2005-07-21 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
EP1695961A4 (en) * 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
WO2005072308A2 (en) * 2004-01-29 2005-08-11 Merck & Co., Inc. Cgrp receptor antagonists
US20050192230A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim International Gambh Process for preparing 1- [N²-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
DE102004006893A1 (de) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von 1[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2008512456A (ja) * 2004-09-09 2008-04-24 メルク エンド カムパニー インコーポレーテッド 三環式アニリドスピロラクタムｃｇｒｐ受容体拮抗薬
ATE518852T1 (de) * 2004-09-13 2011-08-15 Merck Sharp & Dohme Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
EP1770091A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US8291601B2 (en) * 2005-04-01 2012-10-23 Pankaj Kehr Reusable metal blade handle
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
AR127170A1 (es) * 2021-09-30 2023-12-27 Crinetics Pharmaceuticals Inc Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011390A (pt) * 1973-05-30 1975-02-05
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
DE19636623A1 (de) 1996-09-10 1998-03-12 Thomae Gmbh Dr K Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO2000018764A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
MXPA02006509A (es) 2002-11-29
CZ20022628A3 (cs) 2002-10-16
UY26513A1 (es) 2001-07-31
EP1252153A1 (de) 2002-10-30
NZ519939A (en) 2006-08-31
ZA200205181B (en) 2003-09-30
HUP0300002A2 (en) 2003-05-28
AU783275B2 (en) 2005-10-06
BG106848A (bg) 2002-12-29
SK9412002A3 (en) 2002-11-06
KR100736063B1 (ko) 2007-07-06
WO2001049676A1 (de) 2001-07-12
TWI255267B (en) 2006-05-21
IL150377A0 (en) 2002-12-01
YU50002A (sh) 2005-11-28
CA2395541A1 (en) 2001-07-12
CA2395541C (en) 2008-09-23
EE200200369A (et) 2003-10-15
JP2003519222A (ja) 2003-06-17
AU3537901A (en) 2001-07-16
KR20020073493A (ko) 2002-09-26
US20030212057A1 (en) 2003-11-13
DE19963868A1 (de) 2001-07-12
AR027113A1 (es) 2003-03-12
CN1203069C (zh) 2005-05-25
HK1054026A1 (en) 2003-11-14
EA200200651A1 (ru) 2002-12-26
US6949541B2 (en) 2005-09-27
UA75346C2 (en) 2006-04-17
EA005600B1 (ru) 2005-04-28
NO20023161L (no) 2002-06-28
IL150377A (en) 2007-06-17
NO20023161D0 (no) 2002-06-28
HRP20020560A2 (en) 2005-04-30
CN1414960A (zh) 2003-04-30
HUP0300002A3 (en) 2006-01-30
PL356400A1 (en) 2004-06-28
NO323700B1 (no) 2007-06-25

Similar Documents

Publication Publication Date Title
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BRPI0116237B8 (pt) "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
UY27722A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimientos para su preparación.
BRPI0109200B8 (pt) compostos e composições farmacêuticas
BRPI0509368A (pt) antagonistas cgrp selecionados, processo para a sua fabricação bem como seu uso como medicamento
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BR0207715A (pt) Compostos, composições farmacêuticas, e uso de um ou mais compostos
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
BRPI0416276A (pt) lactames macrocìclicos e uso farmacêutico dos mesmos
AR027113A1 (es) Piperidinas sustiutidas, medicamentos que contienen estos compuestos y procedimiento par su preparacion
BR0015147A (pt) Ciclopropanos como cgrp-antagonistas, medicamentos contendo os ditos compostos e processo para a produção dos mesmos
BR0207767A (pt) Derivados de xantina, sua preparação e seu uso como composições farmacêuticas
BR9909688A (pt) Indolinonas substituìdas, a sua preparação e seu uso como composições farmacêuticas
ECSP055746A (es) Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BR9915967A (pt) Derivados de propanolamina substituìdos por arila, proceso para sua preparação, medicamentos contendo estes compostos e seu uso
BR0210464A (pt) Composto, composição farmacêutica, processo para preparar um composto, e, uso de um composto
AR029210A1 (es) DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS
MX9704745A (es) Derivados de piperazina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BR0212069A (pt) Agentes antidiabéticos orais

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.